Vericiguate: a new treatment for chronic heart failure

Download in PDF

The author reviews the pharmacological properties and clinical trials of vericiguate, a stimulant of soluble guanylate cyclase, that is intended for use in patients with chronic heart failure. The new medicine alleviates unfavorable effects of endothelial dysfunction and other disorders associated with a deficiency of bioavailable nitric oxide and suppressed activity of soluble guanylate cyclase. The efficacy of vericiguate in chronic heart failure with a reduced ejection fraction was established in clinical trials SOCRATES-REDUCED and VICTORIA.

Key words

Vericiguate, soluble guanylate cyclase, nitric oxide, endothelial dysfunction, heart failure treatment.